BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29524666)

  • 21. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
    Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
    Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C Degraders.
    Iida T; Itoh Y; Takahashi Y; Yamashita Y; Kurohara T; Miyake Y; Oba M; Suzuki T
    ChemMedChem; 2021 May; 16(10):1609-1618. PubMed ID: 33470543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
    Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
    Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH; Mohamed MS; Ragb EA
    Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
    Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
    Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.
    Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
    Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
    Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
    Ma Y; Zheng Y; Ji Y; Wang X; Ye B
    Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
    Li L; Li R; Wang Y
    Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
    Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
    ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design.
    Alnabulsi S; Al-Hurani EA; Al-Shar'i NA; El-Elimat T
    J Mol Graph Model; 2019 Dec; 93():107440. PubMed ID: 31494535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
    Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
    Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
    Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tertiary sulphonamide derivatives as dual acting small molecules that inhibit LSD1 and suppress tubulin polymerisation against liver cancer.
    Ding L; Wei F; Wang N; Sun Y; Wang Q; Fan X; Qi L; Wang S
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1563-1572. PubMed ID: 34281464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.